Claims for Patent: 6,683,103

Summary for Patent: 6,683,103

Title:	Sulfonamides for treatment of endothelin-mediated disorders
Abstract:	Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.
Inventor(s):	Wu; Chengde (Houston, TX), Blok; Natalie (Houston, TX), Kogan; Timothy (late of Escondido, CA), Keller; Karin (Austin, TX)
Assignee:	Texas Biotechnology Corporation (Houston, TX)
Application Number:	10/029,561
Patent Claims:	1. A compound of formula (I): ##STR18## where Ar.sup.1 is isoxazolyl and Ar.sup.2 has the formula: ##STR19## or a pharmaceutically acceptable derivative thereof, wherein: R.sup.3 and R.sup.4 are independently selected from the group consisting of hydrogen, halo, cyano, cyanoalkyl, C(O)R.sup.41, alkyl, alkenyl, cycloalkyl and aryl, or together form alkylene; W is O, NH or CH.sub.2 ; R.sup.5, R.sup.6 and R.sup.7 are each independently selected as in (i) or (ii), with the proviso that at most one of R.sup.5, R.sup.6 and R.sup.7 is hydrogen: (i) R.sup.6 is hydrogen, unsubstituted alkyl, hydroxy, unsubstituted alkoxy, C(O)R.sup.41, carbamoyloxy or alkoxycarbonyloxy, and R.sup.5 and R.sup.7 are each independently selected from hydrogen, unsubstituted alkyl, hydroxy, C(O)R.sup.41, carbamoyloxy and alkoxycarbonyloxy; or (ii) if at least one of R.sup.3 and R.sup.4 is not hydrogen, then any two may form alkylenedioxy, and the other is selected as in (i); R.sup.45 is selected from the group consisting of alkyl, C(O)R.sup.41, (CH.sub.2).sub.x OH and CH(OH)(CH.sub.2).sub.x CH.sub.3 in which x is 0-6, S(O).sub.n R.sup.41 in which n is 0-2 and C(.dbd.NR.sup.43)R.sup.41 ; R.sup.41 is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, alkylamino, dialkylamino, arylamino, diarylamino, alkylsulfonylamino, arylsulfonylamino, alkylsulfonylalkylamino, alkylsulfonylarylamino, arylsulfonylalkylamino or arylsulfonylarylamino; and R.sup.43 is selected from hydroxy, alkoxy, alkyl and aryl, wherein R.sup.41 and R.sup.43 are unsubstituted or substituted with one or more substituents selected from Y, which is alkoxy, halide, pseudohalide, carboxyl, alkoxycarbonyl, aryloxycarbonyl or hydroxy, with the proviso that the compound is not N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2,4,6-trimethylphenylaminocarbonyl)- thiophene-3-sulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2,4,6-trimethyl)phenylacetyl-3-thiop henesulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-2-[(2,4,6-trimethylphenoxy)carbonyl]thiophen e-3-sulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-[(2,4,6-trimethylphenoxy)carbonyl]thi ophene-3-sulfonamide or N-(4-bromo-3-methyl-5-isoxazolyl)-2-[(2,4,6-trimethylphenoxy)-carbonyl]thi ophene-3-sulfonamide. 2. The compound of claim 1, wherein Ar.sup.1 is 3-isoxazolyl or 5-isoxazolyl. 3. The compound of claim 1, wherein: R.sup.3 and R.sup.4 are each independently hydrogen, alkyl, halo, cyano, cyanomethyl, acetyl or cycloalkyl, or together form alkylene; R.sup.5, R.sup.6 and R.sup.7 are each independently selected as in (i) or (ii), with the proviso that at most one of R.sup.5, R.sup.6 and R.sup.7 is hydrogen: (i) R.sup.6 is hydrogen, unsubstituted alkyl, hydroxy, unsubstituted alkoxy, C(O)R.sup.41, carbamoyloxy or alkoxycarbonyloxy, and R.sup.5 and R.sup.7 are each independently selected from hydrogen, unsubstituted alkyl, hydroxy, C(O)R.sup.4, carbamoyloxy or alkoxycarbonyloxy; or (ii) if at least one of R.sup.3 and R.sup.4 is not hydrogen, then any two may form methylenedioxy, and the other is selected as in (i); x is 0 or 1; n is 2; R.sup.41 is alkyl, cycloalkyl, alkylamino, dialkylamino, arylamino, diarylamino, alkylsulfonylamino or arylsulfonylamino; and R.sup.43 is hydroxy or alkoxy. 4. The compound of claim 1, wherein: Ar.sup.1 is 4-chloro-3-methyl-5-isoxazolyl; R.sup.3 and R.sup.4 are each independently hydrogen, methyl, cyclopropyl, fluoro, chloro, cyano, cyanomethyl or acetyl, or together form propylene; R.sup.5, R.sup.6 and R.sup.7 are each independently selected from (i) or (ii), with the proviso that at most one of R.sup.5, R.sup.6 and R.sup.7 is hydrogen: (i) R.sup.6 is selected from hydrogen, methyl, hydroxy, methoxy, acetyl, carbamoyloxy and methoxycarbonyloxy, and R.sup.5 and R.sup.7 are each independently hydrogen, methyl, hydroxy, acetyl, carbamoyloxy and methoxycarbonyloxy; or (ii) if at least one of R.sup.3 and R.sup.4 is not hydrogen, then R.sup.6 and R.sup.7 may form methylenedioxy and R.sup.5 is selected as in (i); and R.sup.45 is acetyl, propanoyl, 2-methylpropanoyl, cyclopropylcarbonyl, benzoyl, cyclohexylcarbonyl, methyl, 1-hydroxy-1-ethyl, hydroxymethyl, methoxyacetyl, fluoroacetyl, carboxyacetyl, hydroxyacetyl, oximinoacetyl or SO.sub.2 R.sup.41. 5. The compound of claim 1 selected from the group consisting of: N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino)s ulfonyl)-2-thiophenecarboxamide, N-(2-benzoyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-hydroxyethanimidoy l)-4,6-dimethylphenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-propi onylphenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-isobutyryl-4,6-dim ethylphenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(cyclohexylcarbony l)-4,6-dimethylphenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(cyclopropylcarbon yl)-4,6-dimethylphenyl)-2-thiophenecarboxamide, 3-(((3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-thienyl)carbonyl )amino)-2,4,6-trimethylphenyl carbamate, 3-(((3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-thienyl)carbonyl )amino)-2,4,6-trimethylphenyl methyl carbonate, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2-(3-methoxy-2,4,6-trimethylphenyl)ac etyl)-3-thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2-(3-hydroxy-2,4,6-trimethylphenyl)ac etyl)-3-thiophenesulfonamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-hydroxy-1-methy lethyl)-4,6-dimethylphenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-hydroxy-ethyl)- 4,6-dimethylphenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2,6-diacetyl)-4-m ethylphenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-methoxyacetyl)- 4,6-dimethylphenyl)-2-thiophenecarboxamide, 3-(2-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-thienyl)carbonyl)a mino)-3,5-dimethylphenyl)-3-oxopropanoic acid, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-glycolyl-4,6-dimet hylphenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-methy lsulfonyl)phenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-((met hylamino)sulfonyl)phenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-((dim ethylamino)sulfonyl)phenyl)-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-(((me thylsulfonyl)amino)carbonyl)phenyl)-2-thiophenecarboxamide 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-fluoroacetyl)-4 -6-dimethylphenyl)-2-thiophenecarboxamide, N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)aminosu lfonyl)-5-methyl-2-thiophenecarboxamide, N-(2-benzoyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-hydroxyethanimidoy l)-4,6-dimethylphenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-propi onylphenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-isobutyryl-4,6-dim ethylphenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(cyclohexylcarbony l)-4,6-dimethylphenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(cyclopropylcarbon yl)-4,6-dimethylphenyl)-5-methyl-2-thiophenecarboxamide, 3-(((3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-(5-methylthienyl ))carbonyl)amino)-2,4,6-trimethylphenyl carbamate, 3-(((3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-(5-methylthienyl ))carbonyl)amino)-2,4,6-trimethylphenyl methyl carbonate, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2-(3-methoxy-2,4,6-trimethylphenyl) acetyl)-5-methyl-3-thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2-(3-hydroxy-2,4,6-trimethylphenyl)ac etyl)-5-methyl-3-thiophenesulfonamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2(2-hydroxy-1-methyl ethyl)-4,6-dimethylphenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-hydroxy-1-4,6-d imethylphenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2,6-diacetyl)-4-m ethylphenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-methoxyacetyl)- 4,6-dimethylphenyl)-5-methyl-2-thiophenecarboxamide, 3-(2-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-(5-methylthienyl)) carbonyl)amino)-3,5-dimethylphenyl)-3-oxopropanoic acid, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-glycolyl-4,6-dimet hylphenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-methy lsulfonyl)phenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-((met hylamino)sulfonyl)phenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-((dim ethylamino)sulfonyl)phenyl)-5-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-(((me thylsulfonyl)amino)carbonyl)phenyl)-5-methyl-2-thiophenecarboxamide. 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-fluoroacetyl)-4 ,6-dimethylphenyl)-5-methyl-2-thiophenecarboxamide, N-(6-acetyl-4-methyl-1,3-benzodioxol-5-yl)-3-(((4-chloro-3-methyl-5-isoxazo lyl)aminosulfonyl)-5-methyl-2-thiophenecarboxamide, N-(4-acetyl-6-methyl-1,3-benzodioxol-5-yl)-3-(((4-chloro-3-methyl-5-isoxazo lyl)amino)sulfonyl)-5-methyl-2-thiophenecarboxamide, N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino)s ulfonyl)-4-methyl-2-thiophenecarboxamide, N-(2-benzoyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-hydroxyethanimidoy l)-4,6-dimethylphenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-propi onylphenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl) amino)sulfonyl)-N-(2-isobutyryl-4,6-dimethylphenyl)-4-methyl-2-thiopheneca rboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(cyclohexylcarbony l)-4,6-dimethylphenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(cyclopropylcarbon yl)-4,6-dimethylphenyl)-4-methyl-2-thiophenecarboxamide, 3-(((3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-(4-methylthienyl ))carbonyl)amino)-2,4,6-trimethylphenyl carbamate, 3-(((3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-(4-methylthienyl ))carbonyl)amino)-2,4,6-trimethylphenyl methyl carbonate, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2-(3-methoxy-2,4,6-trimethylphenyl)ac etyl)-4-methyl-3-thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2-(3-hydroxy-2,4,6-trimethylphenyl)ac etyl)-4-methyl-3-thiophenesulfonamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-hydroxy-1-methy lethyl)-4,6-dimethylphenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-hydroxy-ethyl)- 4,6-dimethylphenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2,6-diacetyl)-4-m ethylphenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-methoxyacetyl)- 4,6-dimethylphenyl)-4-methyl-2-thiophenecarboxamide, 3-(2-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-(4-methylthienyl)) carbonyl)amino)-3,5-dimethylphenyl)-3-oxopropanoic acid, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-glycolyl-4,6-dimet hylphenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-methy lsulfonyl)phenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-((met hylamino)sulfonyl)phenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-((dim ethylamino)sulfonyl)phenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-(((me thylsulfonyl)amino)carbonyl)phenyl)-4-methyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-fluoroacetyl)-4 ,6-dimethylphenyl)-4-methyl-2-thiophenecarboxamide, N-(6-acetyl-4-methyl-1,3-benzodioxol-5-yl)-3-(((4-chloro-3-methyl-5-isoxazo lyl)amino)sulfonyl)-4-methyl-2-thiophenecarboxamide, N-(4-acetyl-6-methyl-1,3-benzodioxol-5-yl)-3-(((4-chloro-3-methyl-5-isoxazo lyl)amino)sulfonyl)-4-methyl-2-thiophenecarboxamide, N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino)s ulfonyl)-4,5-dimethyl-2-thiophenecarboxamide, N-(2-benzoyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-hydroxyethanimidoy l)-4,6-dimethylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-propi onylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-isobutyryl-4,6-dim ethylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(cyclohexylcarbony l)-4,6-dimethylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(cyclopropylcarbon yl)-4,6-dimethylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-(4,5-dimethylthi enyl))carbonyl)amino)-2,4,6-trimethylphenyl carbamate, 3-(((3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-(4,5-dimethylthi enyl))carbonyl)amino)-2,4,6-trimethylphenyl methyl carbonate, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2-(3-methoxy-2,4,6-trimethylphenyl)ac etyl)-4,5-dimethyl-3-thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(2-(3-hydroxy-2,4,6-trimethylphenyl)ac etyl)-4,5-dimethyl-3-thiophenesulfonamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-hydroxy-1-methy lethyl)-4,6-dimethylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-hydroxy-ethyl)- 4,6-dimethylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2(2,6-diacetyl)-4-me thylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-methoxyacetyl)- 4,6-dimethylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(2-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-2-(4,5-dimethylthien yl))carbonyl)amino)-3,5-dimethylphenyl)-3-oxopropanoic acid, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-glycolyl-4,6-dimet hylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-methy lsulfonyl)phenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-((met hylamino)sulfonyl)phenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-((dim ethylamino)sulfonyl)phenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2,4-dimethyl-6-(((me thylsulfonyl)amino)carbonyl)phenyl)-4,5-dimethyl-2-thiophenecarboxamide, 3-(((4-chloro-3-methyl-5-isoxazolyl)amino)sulfonyl)-N-(2-(2-fluoroacetyl)-4 ,6-dimethylphenyl)-4,5-dimethyl-2-thiophenecarboxamide, N-(6-acetyl-4-methyl-1,3-benzodioxol-5-yl)-3-(((4-chloro-3-methyl-5-isoxazo lyl)amino)sulfonyl)-4,5-dimethyl-2-thiophenecarboxamide, N-(4-acetyl-6-methyl-1,3-benzodioxol-5-yl)-3-(((4-chloro-3-methyl-5-isoxazo lyl)amino)sulfonyl)-4,5-dimethyl-2-thiophenecarboxamide, N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino)s ulfonyl)-5-cyclopropyl-2-thiophenecarboxamide, 5-acetyl-(N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazol yl)amino)sulfonyl)-2-thiophenecarboxamide, N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino)s ulfonyl)-5-cyano-2-thiophenecarboxamide, N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino)s ulfonyl)-5-(cyanomethyl)-2-thiophenecarboxamide, N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino)s ulfonyl)-5-fluoro-2-thiophenecarboxamide, N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino)s ulfonyl)-5-chloro-2-thiophenecarboxamide, and N-2-acetyl-4,6-dimethylphenyl)-5-chloro-3-(((4-chloro-3-methyl-5-isoxazolyl )amino)sulfonyl)-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide. 6. The compound of claim 5 that is a sodium salt. 7. The compound of claim 6 selected from the group consisting of N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-2-thiophenecarboxamide and N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-5-methyl-2-thiophenecarboxamide. 8. The compound of claim 1 selected from the group consisting of N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-2-thiophenecarboxamide and N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-5-methyl-2-thiophenecarboxamide. 9. The compound of claim 1, wherein R.sup.3 and R.sup.4 are hydrogen or methyl. 10. The compound of claim 1, wherein R.sup.3 and R.sup.4 are methyl. 11. The compound of claim 1, wherein R.sup.3 is methyl and R.sup.4 is hydrogen. 12. The compound of claim 1, wherein R.sup.4 is methyl and R.sup.3 is hydrogen. 13. A pharmaceutical composition, comprising the compound of claim 1 in a pharmaceutically acceptable vehicle. 14. The composition of claim 13 that is formulated for oral administration. 15. The composition of claim 13 that is formulated for parenteral administration. 16. The composition of claim 13 that is formulated as a tablet or capsule. 17. A process for preparing a lyophilized powder, comprising: mixing a salt of the compound of claim 1 with a sufficient amount of a solution containing a sugar to produce a solution thereof; sterile-filtering the resulting solution; and lyophilizing the filtered solution to produce a powder. 18. The process of claim 17, wherein the sugar is dextrose or sorbitol. 19. A lyophilized powder produced by the method of claim 17. 20. The powder of claim 19, wherein: the pharmaceutically-acceptable salt is a calcium, lithium, magnesium, potassium, sodium hydrogen phosphate, disodium phosphate, sodium or zinc salt. 21. The powder of claim 19, wherein the pharmaceutically-acceptable salt is a sodium salt. 22. A combination, comprising the powder of claim 19 and a sterile vessel containing a single dosage or multiple dosage amount thereof. 23. The combination of claim 22, wherein the vessel is an ampoule, vial or syringe. 24. A pharmaceutical composition formulated for single dosage or multiple dosage administration prepared by mixing a single dosage of the powder of claim 19 with an aqueous medium. 25. The pharmaceutical composition of claim 24, wherein the final concentration of the sulfonamide salt is between about 1 mg/mL and about 500 mg/mL. 26. A combination comprising: a sterile vial containing the pharmaceutical composition of claim 24. 27. The combination of claim 26, wherein the amount is for single dose administration. 28. The combination of claim 27, wherein the sterile vial also contains an amount of sterile water for injection wherein the final concentration of the sulfonamide sodium salt is 12.5 mg/mL or 25 mg/mL. 29. The composition of claim 16, comprising: about 50-100% by weight of the compound; about 0-25% by weight of an diluent or a binder; about 0-10% by weight of a disintegrant; and about 0-5% of a lubricant. 30. The composition of claim 29, wherein: the binder is microcrystalline cellulose; the diluent is lactose; the disintegrant is microscarmellose sodium or sodium starch glycolate; and the lubricant is magnesium stearate. 31. A method for the treatment of endothelin-mediated diseases, comprising administering an effective amount of the composition of claim 13, wherein the effective amount is sufficient to ameliorate one or more of the symptoms of the disease. 32. The method of claim 31, wherein the compound is a sodium salt of N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-2-thiophenecarboxamide or N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-5-methyl-2-thiophenecarboxamide. 33. The method of claim 31, wherein the disease is selected from the group consisting of hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, ophthalmologic disease, menstrual disorders, obstetric conditions, wounds, gastroenteric disease, renal failure, immunosuppressant-mediated renal vasoconstriction, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock. 34. An article of manufacture, comprising packaging material and a salt of the compound of claim 1 within the packaging material, wherein the compound is effective for antagonizing the effects of endothelin, ameliorating the symptoms of an endothelin-mediated disorder, or inhibiting the binding of an endothelin peptide to an ET receptor with an IC.sub.50 of less than about 10 .mu.M, and the packaging material includes a label that indicates that the compound salt is used for antagonizing the effects of endothelin, inhibiting the binding of endothelin to an endothelin receptor or treating an endothelin-mediated disorder. 35. The article of manufacture of claim 34, wherein the salt is a sodium salt. 36. The article of manufacture of claim 34, wherein the compound is selected from the group consisting of N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-2-thiophenecarboxamide and N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-5-methyl-2-thiophenecarboxamide or salts thereof. 37. The powder of claim 19, wherein the compound is a sodium salt of N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-2-thiophenecarboxamide or N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-5-methyl-2-thiophenecarboxamide. 38. The composition of claim 29, wherein the compound is a sodium salt of N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-2-thiophenecarboxamide or N-(2-acetyl-4,6-dimethylphenyl)-3-(((4-chloro-3-methyl-5-isoxazolyl)amino) sulfonyl)-5-methyl-2-thiophenecarboxamide. 39. An alkali metal salt of 4-chloro-3-methyl-5-(2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)-3-thie nylsulfonamido)isoxazole prepared by a process comprising the steps of: (a) dissolving the free sulfonamide in an organic solvent; (b) washing the dissolved free sulfonamide with a saturated solution of a salt of the alkali metal; and (c) recovering the alkali metal salt of the sulfonamide. 40. The alkali metal salt of claim 39 that is the sodium salt. 41. A method for the treatment of endothelin-mediated diseases, comprising administering an effective amount of the compound of claim 1, wherein the effective amount is sufficient to ameliorate one or more of the symptoms of the disease. 42. The compound of claim 1, wherein Ar.sup.1 has the formula: ##STR20## in which R.sup.1 and R.sup.2 are either (i), (ii) or (iii) as follows: (i) R.sup.1 and R.sup.2 are each independently selected from H, NH.sub.2, NO.sub.2, halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, alkoxy, alkylamino, alkylthio, alkyloxy, haloalkyl, alkylsulfinyl, alkylsulfonyl, aryloxy, arylamino, arylthio, arylsulfinyl, arylsulfonyl, haloalkyl, haloaryl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, arylcarbonyl, formyl, substituted or unsubstituted amido, substituted or unsubstituted ureido, in which the alkyl, alkenyl and alkynyl portions contain from 1 up to about 14 carbon atoms and are either straight or branched chains or cyclic, and the aryl portions contain from about 4 to about 16 carbons, except that R.sup.2 is not halide or pseudohalide; or, (ii) R.sup.1 and R.sup.2 together form --(CH.sub.2).sub.n, where n is 3 to 6; or, (iii) R.sup.1 and R.sup.2 together form 1,3-butadienyl. 43. The compound of claim 42, wherein R.sup.1 is halide or methyl; and R.sup.2 is methyl. 44. The compound of claim 42, wherein R.sup.1 and R.sup.2 are each methyl.

Details for Patent 6,683,103

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2013-10-21